4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors

The compounds are defined by Formula I

• 12
• wherein:
• R1 is hydrogen, hydroxy, C1-C8 alkyl, C1-C8 alkoxy, halo, trifluoromethyl, or CN;
• R2 is hydrogen;
• R3, R4, and R5 independently are hydrogen, hydroxy, halo, trifluoromethyl, C1-C8 alkyl, C1-C8 alkoxy, nitro, CN, or (O or NH)m—(CH2)n—R9, where R9 is hydrogen, hydroxy, CO2H or NR10R 11;
• n is 0 to 4;
• m is 0 or 1;
• R10 and R11 independently are hydrogen or C1-C8 alkyl, or taken together with the nitrogen to which they are attached can complete a 3- to 10-member cyclic ring optionally containing one, two, or three additional heteroatoms selected from O, S, NH, or N—C1-C8 alkyl;
• R6 is hydrogen, C1-C8 alkyl,
• 13
• alkyl, aryl, aralkyl, or C3-C10 cycloalkyl;
• R7 is hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C10 (cycloalkyl or cycloalkyl optionally containing a heterroatom selected from O, S, or NR9);
• and wherein any of the foregoing alkyl, alkenyl, and alkynyl groups can be unsubstituted or substituted by cycloalkyl (or cycloalkyl optionally containing a heteroatom selected from O, S, or NR9), aryl, aryloxy, heteroaryl, or heteroaryloxy;
• or R6 and R7 taken together with the N-0 to which they are attached can complete a 5- to 10-membered cyclic ring, optionally containing one, two, or three additional heteroatoms selected from O, S, or NR10R11.